All In Biotech

Drug Trial Radar · NCT07629726

A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

A Phase 1/2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Apr 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.

Conditions

  • Hematologic Neoplasms

Interventions

  • KK2430Drug

    KK2430 administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Level Toxicity (DLT)Time frame: Endpoint 28 days after first dose
  2. Adverse Events (AEs)Time frame: Signing of ICF through study completion for an average of 1.5 years
  3. Pregnancy TestTime frame: Screening through study completion, an average of 1.5 years
  4. ECG QT IntervalTime frame: Treatment period, an average of 3months
  5. ECG QRS IntervalTime frame: Treatment period, an average of 3months
  6. Vital Sign MeasurementsTime frame: Treatment period, an average of 3 months
  7. Vital Sign MeasurementsTime frame: Treatment period, an average of 3 months
  8. Vital Sign MeasurementsTime frame: Treatment period, an average of 3 months
  9. Vital Sign MeasurementsTime frame: Treatment period, an average of 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Prisma Health

    Greenville, South Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.